Global Psoriasis Drugs Market Professional Survey Report 2019

2 Global Psoriasis Drugs Quarterly Market Size Analysis

• 2.1 Psoriasis Drugs Business Impact Assessment - COVID-19
  • 2.1.1 Global Psoriasis Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Psoriasis Drugs Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Psoriasis Drugs Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Psoriasis Drugs Headquarters and Area Served
• 3.3 Date of Key Players Enter into Psoriasis Drugs Market
• 3.4 Key Players Psoriasis Drugs Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Psoriasis Drugs Segments, By Type

• 4.1 Introduction
  • 1.4.1 Tumor Necrosis Factor Inhibitor
  • 1.4.2 Interleukin Inhibitors
  • 1.4.3 Others
• 4.2 By Type, Global Psoriasis Drugs Market Size, 2019-2021

5 Impact of Covid-19 on Psoriasis Drugs Segments, By Application

• 5.1 Overview
  • 5.5.1 Topicals
  • 5.5.2 Systemic
  • 5.5.3 Biologics
• 5.2 By Application, Global Psoriasis Drugs Market Size, 2019-2021
  • 5.2.1 By Application, Global Psoriasis Drugs Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 AbbVie
  • 7.1.1 AbbVie Business Overview
  • 7.1.2 AbbVie Psoriasis Drugs Quarterly Revenue, 2020
  • 7.1.3 AbbVie Psoriasis Drugs Product Introduction
  • 7.1.4 AbbVie Response to COVID-19 and Related Developments
• 7.2 Amgen
  • 7.2.1 Amgen Business Overview
  • 7.2.2 Amgen Psoriasis Drugs Quarterly Revenue, 2020
  • 7.2.3 Amgen Psoriasis Drugs Product Introduction
  • 7.2.4 Amgen Response to COVID-19 and Related Developments
• 7.3 Johnson & Johnson
  • 7.3.1 Johnson & Johnson Business Overview
  • 7.3.2 Johnson & Johnson Psoriasis Drugs Quarterly Revenue, 2020
  • 7.3.3 Johnson & Johnson Psoriasis Drugs Product Introduction
  • 7.3.4 Johnson & Johnson Response to COVID-19 and Related Developments
• 7.4 Novartis
  • 7.4.1 Novartis Business Overview
  • 7.4.2 Novartis Psoriasis Drugs Quarterly Revenue, 2020
  • 7.4.3 Novartis Psoriasis Drugs Product Introduction
  • 7.4.4 Novartis Response to COVID-19 and Related Developments
• 7.5 Eli Lilly & Company
  • 7.5.1 Eli Lilly & Company Business Overview
  • 7.5.2 Eli Lilly & Company Psoriasis Drugs Quarterly Revenue, 2020
  • 7.5.3 Eli Lilly & Company Psoriasis Drugs Product Introduction
  • 7.5.4 Eli Lilly & Company Response to COVID-19 and Related Developments
• 7.6 AstraZeneca
  • 7.6.1 AstraZeneca Business Overview
  • 7.6.2 AstraZeneca Psoriasis Drugs Quarterly Revenue, 2020
  • 7.6.3 AstraZeneca Psoriasis Drugs Product Introduction
  • 7.6.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.7 Celgene Corporation
  • 7.7.1 Celgene Corporation Business Overview
  • 7.7.2 Celgene Corporation Psoriasis Drugs Quarterly Revenue, 2020
  • 7.7.3 Celgene Corporation Psoriasis Drugs Product Introduction
  • 7.7.4 Celgene Corporation Response to COVID-19 and Related Developments
• 7.8 UCB
  • 7.8.1 UCB Business Overview
  • 7.8.2 UCB Psoriasis Drugs Quarterly Revenue, 2020
  • 7.8.3 UCB Psoriasis Drugs Product Introduction
  • 7.8.4 UCB Response to COVID-19 and Related Developments
• 7.9 Merck
  • 7.9.1 Merck Business Overview
  • 7.9.2 Merck Psoriasis Drugs Quarterly Revenue, 2020
  • 7.9.3 Merck Psoriasis Drugs Product Introduction
  • 7.9.4 Merck Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US